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Background. A phase 3 study demonstrated the safety and efficacy of paromomycin (paromomycin IM injection) for treatment
of VL in an inpatient setting. Methods. This phase 4 study was conducted to assess the safety and efficacy of paromomycin in
children and adults in an outpatient setting in Bihar, India. Results. This study enrolled 506 adult and pediatric patients. Of the
494 patients in the intent-to-treat (ITT) population, 98% received a full course of treatment. The overall study completion rate
was 94% (462/494) for the ITT population and 96% (461/479) for the efficacy-evaluable (EE) population. Initial clinical cure
was 99.6%, and final clinical cure 6 months after treatment was 94.2%. Grade 3 or 4 adverse events occurred in 5% of patients;
events with a frequency of ≥1% were increases in alanine aminotransferase and aspartate aminotransferase. Conclusions. This
study confirms the safety and efficacy of paromomycin to treat VL in an outpatient setting.
1. Introduction
Safe, effective, affordable, and accessible treatments are ur-
gently needed for underserved populations in developing na-
tions who are afflicted with one of the most neglected dis-
eases: visceral leishmaniasis (VL), or kala-azar in South Asia.
VL is endemic in 68 countries, primarily in the developing
world, with an estimated at-risk population of 200 million
[1]. As a systemic disease, VL causes chronic and irregular
fever, weight loss, splenomegaly, hepatomegaly (less fre-
quently), and anemia. If left untreated, VL is almost always
fatal. New drugs are required for the treatment of VL partly
because of the expansion of drug-resistant organisms [2–5].
Antimonials, which were historically the therapeutic
mainstay for treating VL, have decreased effectiveness, espe-
cially in Bihar, India, where, in some cases, up to 65% of pa-
tients are estimated to fail antimonial treatment [3]. Pen-
tamidine is toxic and has lost its initially high level of efficacy;
it is no longer a recommended alternative treatment for VL
[6]. The oral drug miltefosine is expensive and teratogenic,
requiring the coadministration of oral contraceptives for 3
months in women of child-bearing age [7]. Although highly
effective, amphotericin B is expensive, must be infused IV
over 6 hours, is associated with fever, chills, and rigor, can
be nephrotoxic, and requires close clinical and laboratory
monitoring with hospitalization. Studies with lipid formula-
tions of amphotericin B, such as AmBisome or Abelcet, have
shown excellent results both in terms of safety and efficacy.
A recent study showed that AmBisome (liposomal ampho-
tericin B) is highly effective after a single IV infusion, and
a new price agreement for developing countries has made
AmBisome amore affordable treatment option [8]. However,
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because of a continuing concern regarding development of
drug resistance, there continues to be a need for new, safe,
efficacious, and low-cost therapies for the treatment of VL.
Paromomycin is an off-patent aminoglycoside antibiotic
that has been marketed internationally as an oral, topical,
and parenteral drug for bacterial and parasitic infections. In
a phase 2 randomized, open-label, controlled trial of ami-
nosidine (paromomycin) at different doses versus sodium
stibogluconate for treating VL in North Bihar, India, paro-
momycin dosed at 16mg/kg/day for 21 days cured 94% of
cases at 6 months of followup [9, 10]. This study formed the
basis for further development of this drug. Paromomycin was
shown to be safe and effective for treatment of VL in a phase
3 clinical trial in India, with a final cure rate of 94.6% [11].
Paromomycin was subsequently registered for the treatment
of VL in India in 2006 and was included in the WHO Essen-
tial Medicines List in 2007 [12, 13]. The safety profile of
paromomycin along with the approved regimen to treat VL,
intramuscular injection once daily for 21 consecutive days,
should provide better access via the ability to treat patients
in an outpatient setting. This purpose of this phase 4 study
was to confirm the safety and efficacy profile observed in the
phase 3 inpatient study in an outpatient setting.
2. Methods
A phase 4, open-label trial was conducted in two modules
in the state of Bihar. Module 1 was a single-arm pharma-
covigilance trial conducted at seven clinical sites in Bihar and
enrolled 506 adult and pediatric VL patients aged 2–55 years
(NCT00604955). The study was conducted by four research
centers of excellence, including Rajendra Memorial Research
Institute of Medical Sciences; the other three sites had prior
experience conducting phase 4 studies. A 100-patient sub-
study using splenic and bone marrow aspirates for diagnosis
and evaluation of cure was conducted at the Kalazar Research
Centre,Muzaffarpur. The study was conducted in accordance
with the current version of the Declaration of Helsinki, the
Central Drugs Standard Control Organization’s (CDSCO)
Good Clinical Practices (GCP) For Clinical Research In India
(2005), the Indian Council of Medical Research’s (ICMR)
Ethical Guidelines for Biomedical Research on Human Par-
ticipants (2006), and Schedule Y of the Drug and Cosmetics
Act and Rules (amended in 2005). Informed consent was ob-
tained from all adult patients and the parent or legal guardian
of children; when possible, children also provided assent. A
consideration in conducting this clinical study was to expand
capability to conduct clinical trials in rural India in accor-
dance with the International Conference on Harmonisation
(ICH) Guideline for GCP E6 (R1). An external advisory data
and safety monitoring board (DSMB) was established to
conduct periodic reviews of safety.
2.1. Patient Population. Male and female patients aged 2
years (and weighing at least 5 kg) to 55 years with a clinical
diagnosis of VL were eligible to participate in the study. Ex-
clusion criteria included concurrent illness such as HIV,
malaria, and tuberculosis; a history of hearing loss that could
confound clinical detection of potential ototoxicity; recent or
current exposure to medications that could result in com-
pounded toxicities. Before study enrollment, informed con-
sent was obtained from every patient or a legally authorized
representative. After granting informed consent, patients
with suspected VL had their diagnosis confirmed. For pa-
tients with no prior history of VL, a positive recombinant
amastigote antigen K39 (rK39) test confirmed the diagnosis.
The rK39 tests are easy to perform and cost effective, give
reproducible results, and can therefore be used for early
diagnosis of visceral leishmaniasis at both peripheral and
central levels. It is specifically developed for field use and has
good diagnostic accuracy in endemic areas [14]. For patients
with a prior history of VL, a splenic or bone marrow aspirate
with positive parasitology confirmed the diagnosis. In the
100-patient substudy, all patients had splenic or bone mar-
row aspirates to confirm diagnosis and parasitological cure.
2.2. Study Medication, Dose, and Mode of Administration.
Paromomycin (paromomycin IM injection) was provided by
the Institute for OneWorld Health, who sponsored the study.
Paromomycin was manufactured by Gland Pharma Ltd.,
based in Hyderabad, India, and was formulated as a sterile,
aqueous solution containing 375mg/mL of paromomycin
base in a single-use, 2mL, amber, glass ampoule.
Patients with a confirmed diagnosis of VL were screened
for study eligibility within a 7-day screening period prior to
initiation of drug therapy. Patients received the approved
regimen for the treatment of VL in India: paromomycin,
11mg/kg/day as the base, was administered by deep gluteal
intramuscular injection once daily for 21 consecutive days
(22 days if one injection was missed). The dosage (total vol-
ume in milliliters) of paromomycin was based on the pa-
tient’s body weight in kilograms at the screening visit. Pa-
tients returned to the clinical site each day for treatment and
safety assessments. As needed, to facilitate compliance and to
relieve the financial burden of treatment, patients and one
attendant each were provided financial support for transpor-
tation, food, and lodging.
If patients experienced treatment failure or relapse of VL,
they were offered amphotericin B as an alternative (rescue)
treatment for VL. Rescue treatment with amphotericin B
required hospitalization for drug administration.
2.3. Safety and Efficacy Evaluations and Parameters. During
the 21 days of study drug treatment, safety assessments
included daily assessment of treatment-emergent adverse
events (AEs) and SAEs and injection site reactions. Addi-
tionally, patients underwent weekly evaluation of vital signs
and laboratory assessments of renal and hepatic function.
Although no formal audiology assessment was performed,
patients were asked regularly about any subjective changes in
hearing and any auditory and/or vestibular symptoms. Upon
completion of the course of treatment (end of treatment
[EOT]), all patients returned for safety assessments (AEs,
laboratory evaluations, and vital signs) and efficacy assess-
ment of initial clinical cure. Six months after EOT, patients
returned to the clinical site for safety assessments (possibly
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Table 1: Distribution of patients by age and sex.
Baseline characteristic Efficacy-evaluable population (N = 479) Intent-to-treat population (N = 494)
Age category, n (%)
Pediatric (2 to <15 years) 187 (39%) 190 (38%)
2 to <5 years 19 (4%) 19 (4%)
5 to <15 years 168 (35%) 171 (35%)
Adult (≥15 to 55 years) 292 (61%) 304 (62%)
Sex, n (%)
Male 295 (62%) 304 (62%)
Female 184 (38%) 190 (38%)
related and related AEs) and efficacy assessment of final clin-
ical cure. At any time during the initial 6 months after EOT,
patients experiencing VL symptoms could return to the clin-
ical site for an unscheduled visit. At unscheduled visits and
at the scheduled visit 6 months after EOT, patients who ex-
hibited clinical signs and symptoms of VL were identified
and underwent a splenic or bone marrow biopsy to confirm
disease relapse. Final clinical cure was defined as an initial
clinical cure followed by the absence of new clinical signs and
symptoms of VL through 6 months after EOT.
2.4. Statistical Analyses. Although a secondary objective of
the study was to evaluate initial and final clinical cure, the
study was not designed or statistically powered to definitively
measure efficacy in this population. Because this was an
open-label, single-arm study, no formal statistical hypothesis
tests were planned. Descriptive statistics used to summarize
the results were performed using SAS (version 9.1 or higher;
SAS Institute) on a PC platform.
Safety analyses were based on the protocol-specified def-
inition of the intent-to-treat (ITT) population, which in-
cluded all patients who enrolled in the study and received at
least one dose of paromomycin. Efficacy analyses were based
on the efficacy-evaluable (EE) population, which included all
patients without major protocol violations who received at
least 20 doses of paromomycin.
3. Results
3.1. Patient Disposition and Demographics. Of 715 screened
patients, 506 met study entry criteria and were enrolled
(Figure 1). Twelve enrolled patients did not receive study
drug; data for these patients are not presented in this paper
(five did not return to the clinic after screening, one withdrew
consent, two were found to not meet the entry criteria upon
return to the clinic, and four did not receive drug because
the study had fully enrolled). The ITT population was 62%
male, and 38% of patients were pediatric (2 to <15 years old)
(Table 1). The overall study completion rate was 94% (462/
494) for the ITT population and 96% (461/479) for the EE
population. Treatment compliance was high; 485 (98%) pa-
tients received all 21 injections. An additional 15 patients
were excluded from the EE population due to protocol vio-
lations, including patients who received fewer than 20 injec-
715 patients underwent screening
506 were enrolled and assigned to
paromomycin IM injection
494 received the assigned drug
12 did not receive study drug
462 completed the study
2 died
18 had relapse
1 treatment failure
3 withdrew consent
4 discontinued due to AE
4 lost to followup
Figure 1: Disposition of patients in the intent-to-treat population.
tions of study drug and patients for whom a 6-month final
cure assessment was not obtained.
A total of 32 patients (6%) in the ITT population were
prematurely discontinued from the study. The reasons for
premature discontinuation were confirmed relapse (18/32;
56%), AE or nonfatal SAE (4/32; 13%), lost to followup
(4/32; 13%), withdrawal of consent (3/32; 9%), death (2/32;
6%), and confirmed treatment failure (1/32; 3%). In the
EE population, 18 patients (4%) discontinued study partici-
pation prematurely due to confirmed relapse (17/18; 94%)
or treatment failure (1/18; 6%). Patient disposition, demo-
graphics, and disease history were similar across all clinical
sites.
3.2. Efficacy. Initial cure rate, which was assessed at EOT, was
achieved in 99.6% (477/479; 95% CI, 98.5–99.9) patients in
the EE population (Table 2). There was consistency across the
clinical sites based on initial clinical cure rate, which ranged
from 98.3% to 100.0%. Final clinical cure rate, which was
assessed 6months after EOT, was achieved in 94.2% (95%CI,
4 Journal of Tropical Medicine
Table 2: Initial and final clinical cure rates by analysis population.
Analysis population Initial clinical cure rate % (95% CI) Final clinical cure rate % (95% CI)
Efficacy-evaluable population (N = 479) 99.6% (98.5–99.9) 94.2% (91.7–96.1)
Intent-to-treat population (N = 494) 98.4% (96.8–99.3) 91.5% (88.7–93.8)
CI, confidence interval.
91.7–96.1) of 479 patients in the EE population (Table 2).
Of note, data from this long-term clinical cure assessment
was available for all but four patients in the ITT population
who were lost to followup. All VL relapse (N = 18) and
treatment failure (N = 1) patients were subjected to para-
sitological examination through demonstration of L.d. body
in the splenic/bonemarrow aspirates. After confirmation, the
patients (N = 19) were administered with Amphotericin B in
the dose of 1mg per Kg body weight on alternate day for 15
infusions as per the study protocol. In subgroup analyses of
efficacy based on age, sex, and clinical site, initial and final
clinical cure rates across the subgroups were similar in both
the EE and ITT populations, and final clinical cure rates were
lower than initial clinical cure rates.
3.3. Safety and Tolerability. Paromomycin was generally well
tolerated when administered in an outpatient setting. In the
ITT population, 77% of patients reported at least one treat-
ment-emergent AE (Tables 3 and 4). Most patients (91%)
who experienced an AE had an event with a maximum in-
tensity of mild or moderate (i.e., CTCAE grade 1 or 2). The
most frequently reported treatment-emergent AEs (i.e., in-
cidence ≥10%) were increases in CTCAE grade of alanine
aminotransferase (ALT) (52%), aspartate aminotransferase
(AST) (46%), and alkaline phosphatase (16%) as well as in-
jection site pain (10%). Transient increase in levels of hepatic
enzymes, in Kala-Azar patients treated with aminoglycoside
and paromomycin, has been reported in phase III clinical
trial. This may be due to faster destruction of the parasites in
liver tissue in patients [11]. Age and sex appeared to have no
effect on the incidence of AEs, with the exception of injection
site pain and increases in CTCAE grade of creatinine level,
which were reported in a higher percentage of adults (defined
as ≥15 to 55 years of age) than children (no formal statistical
comparisons were made between subgroups).
Severe AEs (i.e., grade 3) included elevations in AST
(18/494; 3.6%) and ALT (8/494; 1.6%), relapse of VL requir-
ing hospitalization for the administration of amphotericin B
(7/494; 1.4%), and single events of increased creatinine, in-
creased bilirubin, injection site pain, injection site reaction,
pneumonia, acute renal failure, tetany, anaemia, and anxiety.
There were four life-threatening (i.e., CTCAE grade 4) AEs
reported, three of which (sudden death, back pain with an
outcome of death, and vaginal haemorrhage) the investigator
considered unrelated to study drug. One patient had a
CTCAE grade 4 (i.e., life-threatening) AE of AST increased
(626.5 U/L; ALT, alkaline phosphatase, and total bilirubin
were not determined) 45 days after EOT that the investigator
classified as possibly related to study drug.
A total of 15 treatment-emergent SAEs were reported:
two fatal events (0.4%) and 13 nonfatal events (2.6%).
Table 3: Summary of treatment-emergent adverse events.
Type of adverse event
Intent-to-treat population
(N = 494)
Treatment-emergent adverse
events, n (%)
Any adverse event 379 (77%)
Treatment related 320 (65%)
Severe or life threateninga 35 (7%)
Led to premature
discontinuation of study drug
5 (1%)
Serious, excluding death 13 (3%)b
Death, n (%) 2 (<1%)c
a
Grade 3 or 4 according to National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) definition.
bTwo events (injection site reaction and renal failure acute) were considered
to be related to study drug.
cBoth deaths were considered not related to study drug.
Neither of the two deaths was considered to be related to
study drug. Two of the 13 nonfatal SAEs were considered
related to study drug: acute renal failure and injection site
reaction. Seven SAEs were relapsing VL that led to per-proto-
col hospitalization of patients for treatment.
Five (1%) patients treated with paromomycin were pre-
maturely discontinued from study drug due to a treatment-
emergent AE, including two events that were considered to be
related to study drug (allergic dermatitis and increased total
bilirubin level).
Other than the one SAE report of acute renal failure, renal
function assessments showed no trend for deterioration. A
mean decrease from baseline to each evaluation timepoint
was observed for tests of renal function (i.e., blood urea
nitrogen [BUN] and creatinine) and total bilirubin (Table 5).
Mean increases from baseline were observed at all evaluation
timepoints for transaminase and alkaline phosphatase levels.
This is reflected in the proportion of patients with associated
AEs that were reported in this study (52%, 46%, and 16% of
patients with increased ALT, AST, and alkaline phosphatase,
resp.). As was seen in the phase 3 trial [11], liver function test
values were increased approximately 20% at weeks 1 and 2
but decreased toward baseline values at EOT. The majority
of subjects had no deterioration from baseline in hepatic
function indices. At the final evaluation, 79% of AST, 69%
of ALT, 92% of alkaline phosphatase, and 99% of bilirubin
values were either low/normal, or, if high, were high at both
baseline and final evaluations. The proportion of subjects
with shifts in transaminase levels from low/normal at base-
line to high at the final evaluation was consistent across time-
points (18–21% for AST and 23–31% for ALT). The majority
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Table 4: Treatment-related and treatment-emergent adverse events in ≥1% of patients.
System organ class CTCAE gradea Total
Preferred term Grade 1 Grade 2 Grade 3 Grade 4 (N = 494)
Any adverse event, n (%) 182 (37%) 116 (23%) 21 (4%) 1 (<1%) 320 (65%)
Investigations, n (%)
Alanine aminotransferase increased 158 (32%) 49 (10%) 7 (1%) 0 (0%) 214 (43%)
Aspartate aminotransferase increased 92 (19%) 75 (15%) 17 (3%) 1 (<1%) 185 (37%)
Blood alkaline phosphatase increased 48 (10%) 11 (2%) 0 (0%) 0 (0%) 59 (12%)
Blood creatinine increased 26 (5%) 5 (1%) 1 (<1%) 0 (0%) 32 (6%)
Blood bilirubin increased 20 (4%) 0 (0%) 1 (<1%) 0 (0%) 21 (4%)
General disorders and administration site conditions, n (%)
Injection site pain 18 (4%) 31 (6%) 1 (<1%) 0 (0%) 50 (10%)
a
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) definition.
of subjects had either a decrease in toxicity grade or no
change in grade; at the final evaluation, 73% of AST, 66% of
ALT, 92% of alkaline phosphatase, and 99% of total bilirubin
values were either the same or a grade decrease from the base-
line value. Across all evaluations, only five (of 7,305; 0.07%)
chemistry values increased more than two grades from the
baseline value. Evaluation of vital signs throughout the study
did not reveal concern associated with the administration of
paromomycin. There were no reports of clinically detected
hearing loss or patient complaints of hearing loss or vestibu-
lar symptoms.
3.4. Occurrence and Outcome of Pregnancies. Pregnant wom-
en were allowed to enroll in the study, and birth control was
not regulated. Three female patients were pregnant at screen-
ing, and one female patient became pregnant more than 1
month after completing treatment. Two of the pregnant pa
tients had AEs of increased AST and increased ALT, both
grade 1. The other two pregnant patients did not report any
AE. In all four pregnancy cases, the offspring were born alive
and were determined to be normal/healthy just after birth.
4. Discussion
Paromomycin administered at 11mg/kg daily for 21 consec-
utive days was generally safe and well tolerated. The efficacy
of paromomycin was confirmed in this study based on long-
term clinical cure in a large and demographically diverse
group of outpatients with either new-onset or relapsing VL.
The study population encompassed children (≥2 years), ado-
lescents, and adults (≤55), including a small number of preg-
nant women. Of note, this study confirmed the efficacy and
safety of PMIM in children below the age of 5, an age group
not previously included in PMIM clinical studies.
Evidence for efficacy in this study is based on the high and
consistent efficacy rates across analyses; the initial clinical
cure at the EOT was 99.6% in the EE population, and final
clinical cure, which was assessed 6 months after EOT, was
94.2% in the EE population. The final clinical cure rate is
consistent with the final clinical cure rate of 94.6% observed
in the phase 3 inpatient clinical study of paromomycin [11].
Increases in levels of liver enzymes have been reported
with medications used to treat VL [4, 7, 15–17]. In this and
prior studies [11] with paromomycin, a peak in liver function
test values occurred after initiation of treatment and then de-
clined toward baseline by EOT. It is unclear whether the hep-
atic effects of VL treatments are a direct result of the drugs or
of a drug-disease interaction.
Although experience with use of paromomycin in preg-
nant women is limited, a teratological study of other amino-
glycoside antibiotic use during pregnancy detected no terato-
genic risk [18], and nonclinical studies have shown that paro-
momycin is not teratogenic, mutagenic, or genotoxic (PMIM
product insert). Paromomycin may be used with caution in
women of childbearing potential [18] (PMIM product in-
sert); pregnant women were allowed to enroll in the study,
and birth control was not regulated. In all four pregnancy
cases in this study, the offspring were born alive and were
determined to be normal/healthy just after birth.
The effect of paromomycin on auditory and vestibular
(cochlear) function has been assessed as part of more general
toxicology studies of paromomycin in animals [19, 20]. The
results of these animal studies indicate that paromomycin
is associated with ototoxicity at high dose levels or at more
moderate dose levels that are administered over extended
periods of time. Paromomycin appears to have an auditory
toxicity profile similar to that of amikacin and kanamycin; its
vestibular effects are minor, occurring at high doses and in
only a few animal species. Ototoxicity was not formally stud-
ied in this phase 4 study. There were no reports of clinically
detected hearing loss or patient complaints of hearing loss or
vestibular symptoms in this study although transient reversi-
ble ototoxicity was observed in 2% of subjects the phase 3
trial with paromomycin [11].
Although intramuscular treatments can be challenging
for widespread public health use, patient compliance at the
participating clinics was high. Food, lodging, and transporta-
tion were provided for each patient and a caregiver, which
likely contributed to the high compliance rate. Primary
health-center personnel have experience with intramuscular
administration of other treatments, and supervised dosing
may help decrease the risk of development of parasitic resist-
ance caused by noncompliance.
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Table 5: Mean change from baseline to study day 8, study day 15,
and EOT/ET for tests of liver and renal function.
Indice
Mean (SD) Visit
Value
Mean (SD) Change
from Baseline
AST (U/L)
Baseline (N = 494) 52.89 (27.16)
Day 8 (N = 489) 73.54 (72.01) 20.47 (67.13)
Day 15 (N = 486) 64.36 (48.60) 11.26 (49.75)
EOT/ETa (N = 486) 58.37 (26.21) 5.28 (32.65)
ALT (U/L)
Baseline (N = 494) 39.62 (27.25)
Day 8 (N = 489) 58.22 (70.62) 18.50 (62.96)
Day 15 (N = 486) 58.17 (54.35) 18.39 (52.00)
EOT/ETa (N = 486) 51.83 (30.18) 12.05 (32.64)
Alkaline phosphatase (U/L)
Baseline (N = 494) 229.00 (127.84)
Day 8 (N = 489) 261.70 (168.80) 31.92 (129.97)
Day 15 (N = 486) 261.60 (137.59) 32.12 (114.93)
EOT/ETa (N = 486) 254.23 (119.51) 24.75 (116.80)
Bilirubin total (mg/dL)
Baseline (N = 494) 0.60 (0.26)
Day 8 (N = 489) 0.57 (0.37) −0.03 (0.38)
Day 15 (N = 486) 0.56 (0.23) −0.03 (0.29)
EOT/ETa (N = 486) 0.57 (0.22) −0.03 (0.29)
BUN (mg/dL)
Baseline (N = 494) 12.58 (4.15)
Day 8 (N = 489) 10.20 (3.32) −2.33 (4.55)
Day 15 (N = 486) 11.07 (3.64) −1.46 (4.66)
EOT/ETa (N = 486) 11.54 (4.39) −0.99 (5.35)
Serum creatinine (mg/dL)
Baseline (N = 494) 0.83 (0.26)
Day 8 (N = 489) 0.75 (0.25) −0.08 (0.20)
Day 15 (N = 486) 0.75 (0.26) −0.09 (0.23)
EOT/ETa (N = 486) 0.75 (0.30) −0.09 (0.28)
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
aEnd of treatment or early termination.
5. Conclusions
In conclusion, paromomycin was shown to be efficacious
when used in an outpatient setting. With the exception of in-
creases in liver function test parameters, which decreased
toward baseline over time, paromomycin has a reasonable
safety profile, including demonstrated safety and efficacy in
pediatric patients and, with limited data thus far, in pregnant
women. Coupled with its relatively low cost, paromomycin is
an accessible therapy for the treatment of VL.
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